v2.4.0.8
Condensed Consolidated Statement of Cash Flows (USD $)
In Millions, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Cash Flow From (Used in) Operating Activities:    
Net earnings $ 841 $ 1,021
Adjustments to reconcile net earnings to net cash from operating activities -    
Depreciation 463 461
Amortization of intangibles 335 396
Share-based compensation 168 177
Trade receivables (76) (91)
Inventories (141) (232)
Other, net (354) (555)
Net Cash From Operating Activities 1,236 1,177
Cash Flow From (Used in) Investing Activities:    
Acquisitions of property and equipment (513) (565)
Sales (Purchases) of investment securities, net 1,119 (1,507)
Other 27  
Net Cash From (Used in) Investing Activities 633 (2,072)
Cash Flow From (Used in) Financing Activities:    
Proceeds from issuance of short-term debt and other 872 3,150
Transfer of cash and cash equivalents to AbbVie Inc.   (5,901)
Purchases of common shares (2,193) (1,215)
Proceeds from stock options exercised, including income tax benefit 226 142
Dividends paid (676) (444)
Net Cash (Used in) Financing Activities (1,771) (4,268)
Effect of exchange rate changes on cash and cash equivalents (3) (67)
Net Increase (Decrease) in Cash and Cash Equivalents 95 (5,230)
Cash and Cash Equivalents, Beginning of Year 3,475 10,802
Cash and Cash Equivalents, End of Period $ 3,570 $ 5,572